Literature DB >> 3013520

Immunization against bovine papillomavirus infection.

W P Pilacinski, D L Glassman, K F Glassman, D E Reed, M A Lum, R F Marshall, C C Muscoplat, A J Faras.   

Abstract

The two large open reading frames denoted L1 and L2 in the non-transforming region of the bovine papillomavirus type 1 (BPV-1) genome have been molecularly cloned to expression in Escherichia coli. Antisera against the E. coli-derived L1 and L2 protein reacted with BPV-1 in both enzyme-linked immunosorbent assays and immunoprecipitation reactions. Neutralization of BPV-induced transformation of mouse C127 cells was demonstrated most consistently with antisera against the L1 protein. E. coli-derived L1 protein protected calves against BPV-1 challenge after vaccination.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3013520     DOI： 10.1002/9780470513309.ch10

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN： 0300-5208


  14 in total

1.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors:  Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

Review 2.  [Prophylactic and therapeutic HPV immunization].

Authors:  M Müller; L Gissmann
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

Review 3.  Progress and prospects for L2-based human papillomavirus vaccines.

Authors:  Rosie T Jiang; Christina Schellenbacher; Bryce Chackerian; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2016-03-10       Impact factor: 5.217

4.  Regression of papillomas induced by cottontail rabbit papillomavirus is associated with infiltration of CD8+ cells and persistence of viral DNA after regression.

Authors:  R Selvakumar; A Schmitt; T Iftner; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  A multimeric L2 vaccine for prevention of animal papillomavirus infections.

Authors:  Subhashini Jagu; Nicole Malandro; Kihyuck Kwak; Hang Yuan; Richard Schlegel; Kenneth E Palmer; Warner K Huh; M Saveria Campo; Richard B S Roden
Journal:  Virology       Date:  2011-09-13       Impact factor: 3.616

6.  Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

Authors:  D Nardelli-Haefliger; R B Roden; J Benyacoub; R Sahli; J P Kraehenbuhl; J T Schiller; P Lachat; A Potts; P De Grandi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

7.  Identification of the human papillomavirus type 6b L1 open reading frame protein in condylomas and corresponding antibodies in human sera.

Authors:  C C Li; K V Shah; A Seth; R V Gilden
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

8.  Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product.

Authors:  Y L Lin; L A Borenstein; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

10.  Lack of effect of recombinant bovine interferon alpha I1 in the treatment of experimentally-induced bovine warts.

Authors:  M L Lassauzet; P A Salamin
Journal:  Can J Vet Res       Date:  1993-07       Impact factor: 1.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.